This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS
Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemo-radiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma. A randomized clinical trial. JAMA Surg 2021; 156: 444-451.
Published: 24th November 2021
Authors: Wang H, Tang H, Fang Y, Tan L, Yin J, Shen Y et al.
The addition of radiotherapy to neoadjuvant chemotherapy was tested in this study that included 264 patients. There was no difference in perioperative morbidity or mortality. Additional radiotherapy improved the complete pathological response rate (35.7 versus 3.8 per cent, P<0.001) and the rate of negative lymph nodes (66.1 versus 46.2 per cent, P=0.03), but did not improve one year survival.Pubmed Link
You may also be interested in
Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021; 384: 1191-1203.
Authors: Kelly RJ, Ajani JA, Kuzdzal J, Zander T, van Cutsem E, Piessen G et al.
Surgical morbidity and mortality from the multicenter randomized controlled NeoRes II Trial. Standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 2020; 272: 684-689.
Authors: Nilsson K, Klevebro F, Rouvelas I, Lindblad M, Szabo E, Halldestam I et al.
Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer. A randomized clinical trial. JAMA Surg 2019; 154: 1093-1101
Authors: Li Z, Shan F, Ying X, Zhang Y, E J-Y, Wang Y et al.
Authors: Choi IJ, Kim CG, Lee JY, Kim Y-I, Kook M-C, Park B et al.
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948-1957.
Authors: Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al.
Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol 2018; 36: 2796-2803.
Authors: Yang H, Liu Y, Chen Y, Zhu C, Fang W, Yu Z et al.
Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). EJSO 2017; 43: 1550-1558.
Authors: Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Nowak K, Kieser M et al.
Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis. Ann Surg 2017; 265: 481-491.
Authors: Pasquali S, Yim G, Vohra R , Mocellin S, Nyanhongo D, Marriott P et al.
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol 2017; 18: 357-370.
Authors: Cunningham D, Stenning SP , Smyth EC, Okines AF, Allum WH, Rowley S et al.
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 2014; 32: 2416-2422.
Authors: Mariette C, Dahan L, Mornex F, Maillard E, Thomas P-A, Meunier B et al. et al.
Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084.
Authors: Van Hagen P, Hulsof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MIBV, Wijnhoven BPL et al. et al.
Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387–4393.
Authors: Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T et al. et al.